阿法替尼联合利巴韦林及每周卡铂紫杉醇诱导化疗治疗IVA/IVB期HPV相关口咽鳞癌的I期研究
该I期剂量递增研究评估在紫杉醇和卡铂诱导化疗基础上加用阿法替尼和利巴韦林,治疗HPV相关局部晚期口咽鳞癌。10例患者中未出现剂量限制性毒性,6例(67%)获未经确认的部分缓解,2年无进展生存率为75%。结论认为该方案安全耐受,阿法替尼II期推荐剂量为口服每日40 mg。
要点
- 阿法替尼联合利巴韦林及卡铂紫杉醇诱导化疗在HPV相关口咽鳞癌中安全耐受。
- 10例患者中6例(67%)达未经确认的部分缓解,2年无进展生存率75%。
- 阿法替尼在该联合方案中的II期推荐剂量为口服每日40 mg。
核心结论
- 阿法替尼、利巴韦林、紫杉醇和卡铂诱导化疗安全且耐受良好。
- 该联合方案中阿法替尼的II期推荐剂量为口服每日40 mg。
研究设计与样本
- I期剂量递增研究,纳入10例HPV相关局部晚期口咽鳞癌患者。
- 阿法替尼设30 mg和40 mg每日口服两个剂量水平,利巴韦林按体重给药。
- 紫杉醇80 mg/m2和卡铂AUC 1.5于每21天周期第1、8天给药,3周期后出组接受根治性治疗。
主要发现
- 10例患者中未出现剂量限制性毒性。
- 6例患者(67%)达到未经确认的客观部分缓解。
- 2年无进展生存率为75%。
关键数值与推荐
- 阿法替尼II期推荐剂量为口服每日40 mg。
- 紫杉醇剂量80 mg/m2,卡铂AUC 1.5,每21天周期第1、8天给药。
临床怎么用
- 该方案可作为HPV相关局部晚期口咽鳞癌诱导化疗的候选方案,后续需II期研究验证。
局限性
- 样本量仅10例,为I期剂量递增研究。
- 疗效为未经确认的部分缓解,缺乏对照。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The human papillomavirus (HPV) E6 oncoprotein enhances the oncogenic potential of ErbB proteins in HPV-related malignancies. This phase I study evaluates the addition of afatinib, an ErbB family inhibitor, and ribavirin to paclitaxel and carboplatin induction chemotherapy in HPV-associated, locally advanced oropharyngeal squamous cell carcinoma (SCC). METHODS: This dose escalation study included 2 doses of oral afatinib: 30 and 40 mg daily. Ribavirin dosing was weight based. Paclitaxel (80 mg/m2 ) and carboplatin (area under the curve [AUC] 1.5) were administered on days 1 and 8 of each 21-day cycle. After 3 cycles, patients were removed from protocol to receive definitive treatment. RESULTS: Among 10 patients, there were no dose-limiting toxicities. Six patients (67%) had unconfirmed objective partial responses. The 2-year progression-free survival rate was 75%. CONCLUSION: Afatinib, ribavirin, paclitaxel, and carboplatin induction chemotherapy is safe and well tolerated. The phase II recommended dose of afatinib is 40 mg oral daily in this combination regimen.
引用
- Dunn LA, Fury MG, Sherman EJ, et al. Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer. Head Neck. 2017. PMID: 28963790. doi:10.1002/hed.24938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。